Format

Send to

Choose Destination
Pharmacogenomics. 2016 Oct;17(15):1693-1706. Epub 2016 Oct 10.

A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.

Author information

1
Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.
2
Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
3
Division of General Cardiology, Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
4
McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada.
5
Programs for Assessment of Technology in Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
6
Beaulieu-Saucier Pharmacogenomics Centre, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.

Abstract

Pharmacogenomics (PGx) tests have the potential of improving the effectiveness of expensive new drugs by predicting the likelihood, for a particular patient, to respond to a treatment. The objective of this study was to develop a pharmacoeconomic model to determine the characteristics and the cost-effectiveness of a hypothetical PGx test, which would identify patients who are most likely to respond to an expensive treatment for chronic heart failure. For this purpose, we chose the example of ivabradine. Our results suggest that the use of a PGx test that could select a subgroup of patients to be treated with an expensive drug has the potential to provide more efficient drug utilization.

KEYWORDS:

Markov model; New York Heart Association; cardiovascular diseases; chronic heart failure; cost%ndash;effectiveness; pharmacogenomics tests; quality-adjusted life years

PMID:
27719379
DOI:
10.2217/pgs-2016-0054

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center